Clinical Trial Update: Phase IB/II of CPX-351 for Relapse Prevention in AML [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CPX-351 for relapse prevention in acute myeloid leukemia in remission; the Phase 1/Phase 2 study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Georgetown University | Conditions: Acute Myeloid Leukemia (AML) in Remission | Phase 1, Phase 2 | Status: RECRUITING